TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users. A Double Blind, Placebo Controlled Trial
Brief Summary: Primary aim: Will varenicline be better than placebo to get long-term users of NRT to stop?

Secondary aim: To assess in details some side effects of varenicline i.e. nausea and abnormal dreams.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users. A Double Blind, Placebo Controlled Trial
Brief Summary: Primary aim: Will varenicline be better than placebo to get long-term users of NRT to stop?

Secondary aim: To assess in details some side effects of varenicline i.e. nausea and abnormal dreams.


Options:
A: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: Varenicline + Active Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Varenicline | Arm Label: Varenicline + Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Varenicline + Active Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Patch, Varenicline + Placebo Patch
C: Arm Label: Motivational Text Messages; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Text Messages | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Motivational Text Messages; Assigned to Arm(s): Motivational Text Messages | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
D: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users. A Double Blind, Placebo Controlled Trial
Brief Summary: Primary aim: Will varenicline be better than placebo to get long-term users of NRT to stop?

Secondary aim: To assess in details some side effects of varenicline i.e. nausea and abnormal dreams.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
C: Arm Label: 1: Bup+MM; Type: EXPERIMENTAL; Interventions: Drug: bupropion, Behavioral: Medication Management, Drug: placebo patch | Arm Label: 2 Bup+Mayo; Type: EXPERIMENTAL; Interventions: Drug: bupropion, Behavioral: Mayo Counseling, Drug: placebo patch | Arm Label: 3 Patch+MM; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal system, Behavioral: Medication Management, Drug: placebo bupropion | Arm Label: 4 Patch+Mayo; Type: EXPERIMENTAL; Interventions: Drug: nicotine transdermal system, Behavioral: Mayo Counseling, Drug: placebo bupropion | Intervention Type: DRUG; Name: nicotine transdermal system; Assigned to Arm(s): 3 Patch+MM, 4 Patch+Mayo | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 1: Bup+MM, 2 Bup+Mayo | Intervention Type: BEHAVIORAL; Name: Medication Management; Assigned to Arm(s): 1: Bup+MM, 3 Patch+MM | Intervention Type: BEHAVIORAL; Name: Mayo Counseling; Assigned to Arm(s): 2 Bup+Mayo, 4 Patch+Mayo | Intervention Type: DRUG; Name: placebo patch; Assigned to Arm(s): 1: Bup+MM, 2 Bup+Mayo | Intervention Type: DRUG; Name: placebo bupropion; Assigned to Arm(s): 3 Patch+MM, 4 Patch+Mayo
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users. A Double Blind, Placebo Controlled Trial
Brief Summary: Primary aim: Will varenicline be better than placebo to get long-term users of NRT to stop?

Secondary aim: To assess in details some side effects of varenicline i.e. nausea and abnormal dreams.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A
D: Arm Label: Order 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 2; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 3; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Arm Label: Order 4; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Nasal Spray, Drug: Varenicline, Drug: Placebo Nasal Spray, Drug: Placebo Varenicline | Intervention Type: DRUG; Name: Nicotine Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Nasal Spray; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4 | Intervention Type: DRUG; Name: Placebo Varenicline; Assigned to Arm(s): Order 1, Order 2, Order 3, Order 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users. A Double Blind, Placebo Controlled Trial
Brief Summary: Primary aim: Will varenicline be better than placebo to get long-term users of NRT to stop?

Secondary aim: To assess in details some side effects of varenicline i.e. nausea and abnormal dreams.


Options:
A: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Tailored/No Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended Tailored Counseling + NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Intervention Type: DRUG; Name: Nicotine polacrilex, Bupropion; Assigned to Arm(s): Brief Treatment, Extended NRT, Extended Tailored Counseling + NRT, Tailored/No Extended NRT

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N-methylglycine (Sarcosine) for Treatment of Major Depressive Disorder
Brief Summary: Major depressive disorder is a complex disease and most currently available antidepressants aiming at monoamine neurotransmission exhibit limited efficacy and cognitive effects. N-methyl-D-aspartate (NMDA), one subtype of glutamate receptors, plays an important role in learning and memory. N-methyl-D-aspartic acid (NMDA) enhancing agents, such as sarcosine (N-methylglycine), have been used as adjunctive therapy of schizophrenia. Sarcosine improved not only psychotic but also depressive symptoms in patients with schizophrenia. To confirm its antidepressant effect, the purpose of this study is to compare citalopram and sarcosine in efficacy for major depressive patients.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RO4995819 15 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4995819 | Arm Label: RO4995819 30 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4995819 | Arm Label: RO4995819 5 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4995819 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RO4995819; Assigned to Arm(s): RO4995819 5 mg | Intervention Type: DRUG; Name: RO4995819; Assigned to Arm(s): RO4995819 15 mg | Intervention Type: DRUG; Name: RO4995819; Assigned to Arm(s): RO4995819 30 mg
B: Arm Label: Esketamine low dose; Type: EXPERIMENTAL; Interventions: Drug: Esketamine DPI - low dose | Arm Label: Esketamine medium dose; Type: EXPERIMENTAL; Interventions: Drug: Esketamine DPI - medium dose | Arm Label: Esketamine high dose; Type: EXPERIMENTAL; Interventions: Drug: Esketamine DPI - high dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo DPI | Intervention Type: DRUG; Name: Esketamine DPI - low dose; Assigned to Arm(s): Esketamine low dose | Intervention Type: DRUG; Name: Esketamine DPI - medium dose; Assigned to Arm(s): Esketamine medium dose | Intervention Type: DRUG; Name: Esketamine DPI - high dose; Assigned to Arm(s): Esketamine high dose | Intervention Type: DRUG; Name: Placebo DPI; Assigned to Arm(s): Placebo
C: Arm Label: sarcosine; Type: EXPERIMENTAL; Interventions: Drug: sarcosine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: sarcosine; Assigned to Arm(s): sarcosine
D: Arm Label: Riluzole; Type: EXPERIMENTAL; Interventions: Drug: Riluzole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riluzole; Assigned to Arm(s): Riluzole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Crossover, Open-label Phase 1 Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)
Brief Summary: To determine the safety and tolerability of single oral doses of HPN-100 as a formulation (GT4P-F) and GT4P as the active pharmaceutical ingredient (GT4P-API) administered to healthy male subjects.


Options:
A: Arm Label: HPN-100; Type: EXPERIMENTAL; Interventions: Drug: HPN-100 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HPN-100; Assigned to Arm(s): HPN-100 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: GT4P-F; Type: EXPERIMENTAL; Interventions: Drug: HPN-100 | Arm Label: GT4P-API; Type: EXPERIMENTAL; Interventions: Drug: HPN-100 | Arm Label: Ammonul; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ammonul | Arm Label: Buphenyl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buphenyl | Intervention Type: DRUG; Name: HPN-100; Assigned to Arm(s): GT4P-API, GT4P-F | Intervention Type: DRUG; Name: Ammonul; Assigned to Arm(s): Ammonul | Intervention Type: DRUG; Name: Buphenyl; Assigned to Arm(s): Buphenyl
C: Arm Label: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®); Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®) | Arm Label: Lactulose; Type: OTHER; Interventions: Drug: Lactulose | Intervention Type: DRUG; Name: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®); Assigned to Arm(s): Polyethylene glycol 3350-electrolyte solution (GoLYTELY®) | Intervention Type: DRUG; Name: Lactulose; Assigned to Arm(s): Lactulose
D: Intervention Type: DRUG; Name: HPN-100; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised, Multi-Centre, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation in Patients With Chronic Obstructive Pulmonary Disease
Brief Summary: The study null hypothesis is that vitamin D supplementation will not influence time to upper respiratory tract infection or time to moderate/severe exacerbation of chronic obstructive pulmonary disease.


Options:
A: Arm Label: Vitamin D3 100,000 IU; Type: EXPERIMENTAL; Interventions: Drug: Experimental: Vitamin D3 100,000 IU | Arm Label: Vitamin D3 12,000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active Comparator: Vitamin D3 12,000 IU | Intervention Type: DRUG; Name: Experimental: Vitamin D3 100,000 IU; Assigned to Arm(s): Vitamin D3 100,000 IU | Intervention Type: DRUG; Name: Active Comparator: Vitamin D3 12,000 IU; Assigned to Arm(s): Vitamin D3 12,000 IU
B: Arm Label: Vigantol oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Arm Label: Miglyol oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Miglyol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Vigantol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Miglyol oil; Assigned to Arm(s): Miglyol oil
C: Arm Label: Reuterin D3 drops; Type: ACTIVE_COMPARATOR; Interventions: Drug: Reuterin D3 drops | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Reuterin D3 drops; Assigned to Arm(s): Reuterin D3 drops | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Arm Label: Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised, Multi-Centre, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation in Patients With Chronic Obstructive Pulmonary Disease
Brief Summary: The study null hypothesis is that vitamin D supplementation will not influence time to upper respiratory tract infection or time to moderate/severe exacerbation of chronic obstructive pulmonary disease.


Options:
A: Arm Label: 2000 IU per day vitamin D; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 - Cholecalciferol 2000 IU | Arm Label: 400 IU per day vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D - Cholecalciferol 400 IU | Intervention Type: DRUG; Name: Vitamin D - Cholecalciferol 400 IU; Assigned to Arm(s): 400 IU per day vitamin D | Intervention Type: DRUG; Name: Vitamin D3 - Cholecalciferol 2000 IU; Assigned to Arm(s): 2000 IU per day vitamin D
B: Arm Label: Vigantol oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Arm Label: Miglyol oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Miglyol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Vigantol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Miglyol oil; Assigned to Arm(s): Miglyol oil
C: Arm Label: Ciclesonide + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: Ciclesonide + Vitamin D; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3, Drug: Ciclesonide | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Ciclesonide + Vitamin D | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide + Vitamin D, Ciclesonide + placebo
D: Arm Label: Vigantol oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Arm Label: Miglyol oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Miglyol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Vigantol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Miglyol oil; Assigned to Arm(s): Miglyol oil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of NEC in Preterm Infants With B. Lactis
Brief Summary: The purpose of the trial is to demonstrate the effect of B. lactis in reducing the incidence of Necrotizing Enterocolitis (NEC) compared to placebo in preterm infants.


Options:
A: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium bifidum supplementation | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo contains dextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium bifidum supplementation; Assigned to Arm(s): Active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo contains dextrin; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VSL#3 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VSL#3; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: "Milk" containing B. Lactis; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic supplementation | Arm Label: "Milk" containing placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Milk containing placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic supplementation; Assigned to Arm(s): "Milk" containing B. Lactis | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk containing placebo; Assigned to Arm(s): "Milk" containing placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of NEC in Preterm Infants With B. Lactis
Brief Summary: The purpose of the trial is to demonstrate the effect of B. lactis in reducing the incidence of Necrotizing Enterocolitis (NEC) compared to placebo in preterm infants.


Options:
A: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium bifidum supplementation | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo contains dextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium bifidum supplementation; Assigned to Arm(s): Active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo contains dextrin; Assigned to Arm(s): Placebo
B: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group
C: Arm Label: "Milk" containing B. Lactis; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic supplementation | Arm Label: "Milk" containing placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Milk containing placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic supplementation; Assigned to Arm(s): "Milk" containing B. Lactis | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk containing placebo; Assigned to Arm(s): "Milk" containing placebo
D: Arm Label: Bifidobacterium lactis plus inulin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Arm Label: maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis plus inulin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium lactis plus inulin; Assigned to Arm(s): maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Bifidobacterium lactis plus inulin

Answer: C